Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
<p>Cell type predictive of treatment efficacy. Cell type differences of (a) partial response vs non-partial responders (b) progression-free survival longer vs shorter than 6 months by MCP-Counter. All p-values were derived from non-parametric Wilcoxon test.</p>
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Weitere Verfasser: | , , , , , , , , , , , |
| Veröffentlicht: |
2025
|
| Schlagworte: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|